| Patient | Elizabeth Barrett Browning |
|---|---|
| Date of birth | 1987-03-06 |
| Identifiers | MRN HR-NI026-SYN; SSN (made up) 000-26-4157 |
| Document date | 2026-11-01 |
| Author | Clementine Haverford-Asante, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for chronic cough with blood-streaked sputum, a long-term opioid prescription, and grief, with tuberculosis testing and urgent pulmonology referral. Concerns: She has coughed for years and lately sees streaks of blood; she wants to know whether it is consumption; She worries that the morphine she has taken for so long is harming her, but fears being made to stop it; She wants to keep writing, and to be able to think of her brother without being overwhelmed. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Morphine sulfate 2 mg/mL oral solution, 5 mL (10 mg) by mouth twice daily, morning and bedtime (20 mg a day; long-standing prescription, continued) | 5 mL (10 mg) twice daily, morning and bedtime | Oral route | 2019-03-01 to 2026-04-19 | completed | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911 | As needed for suspected overdose; keep two devices at home | Nasal route | 2026-03-16 | active | S |
| Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (2000 units) by mouth daily | Two tablets daily | Oral route | 2026-03-16 | active | S |
| Amoxicillin 500 mg oral capsule, one capsule by mouth three times daily for 14 days | One capsule three times daily for 14 days | Oral route | 2026-08-10 to 2026-08-23 | completed | S |
| Morphine sulfate 2 mg/mL oral solution, 4.5 mL (9 mg) by mouth twice daily, morning and bedtime (18 mg a day) | 4.5 mL (9 mg) twice daily, morning and bedtime | Oral route | 2026-04-20 to 2026-06-14 | completed | S |
| Morphine sulfate 2 mg/mL oral solution, 4 mL (8 mg) by mouth twice daily, morning and bedtime (16 mg a day) | 4 mL (8 mg) twice daily, morning and bedtime | Oral route | 2026-06-15 to 2026-10-18 | completed | S |
| Morphine sulfate 2 mg/mL oral solution, 3.5 mL (7 mg) by mouth twice daily, morning and bedtime (14 mg a day) | 3.5 mL (7 mg) twice daily, morning and bedtime | Oral route | 2026-10-19 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| CT of the chest with intravenous contrast and thin-section reconstructions | 2026-03-23 to 2026-03-23 | completed | S |
| Spirometry before and after bronchodilator | 2026-03-23 to 2026-03-23 | completed | S |
| Bone density scan (DXA) of the lumbar spine and hip | 2026-04-20 to 2026-04-20 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-07-13 to 2026-07-13 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-07-13 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
| 2026-07-13 | Pneumococcal conjugate vaccine, 20-valent (PCV20) | completed | S |
| 2026-07-13 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-10-19 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 2026-10-19 | Influenza vaccine, inactivated, this season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1821 | Serious illness at about fifteen, from which she nearly died, treated at a spa for most of a year; a spinal injury, later attributed to a strain, contributed to lasting weakness; a prescribed opiate from then on | D (CLM-0002, CLM-0003, CLM-0004) |
| 1838 | Chest illness with blood in the sputum (described as a broken blood vessel), judged by her physicians to be an affection of the lungs but not tubercular consumption; largely confined indoors since | D (CLM-0005, CLM-0011) |
| 1840 | Severe decline in health after the drowning of her brother, with slow recovery over the following winter | D (CLM-0007, CLM-0008) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died after a last illness when the patient was in her early twenties; cause not recorded in the cited source | D (CLM-0010) | |
| brother | Died by accidental drowning in a sailing accident five years ago | D (CLM-0007) | |
| brother | Died abroad earlier in the same year; cause not recorded in the cited source | D (CLM-0009) |
| Concern | Status | Evidence |
|---|---|---|
| She has coughed for years and lately sees streaks of blood; she wants to know whether it is consumption | active | S |
| She worries that the morphine she has taken for so long is harming her, but fears being made to stop it | active | S |
| She wants to keep writing, and to be able to think of her brother without being overwhelmed | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 12.3 on 2026-03-16; MCV [Entitic mean volume] in Red Blood Cells by Automated count 88 on 2026-03-16; Leukocytes [#/volume] in Blood by Automated count 11.8 on 2026-08-10; Eosinophils [#/volume] in Blood 0.21 on 2026-03-16; Platelets [#/volume] in Blood by Automated count 352 on 2026-03-16; C reactive protein [Mass/volume] in Serum or Plasma 38 on 2026-08-10; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-03-16; Potassium [Moles/volume] in Serum or Plasma 4.1 on 2026-03-16; Creatinine [Mass/volume] in Serum or Plasma 0.66 on 2026-03-16; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 114 on 2026-03-16; Glucose [Mass/volume] in Serum or Plasma 84 on 2026-03-16; Calcium [Mass/volume] in Serum or Plasma 9.2 on 2026-03-16; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 2026-06-15; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 on 2026-10-19; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 2026-06-15; FEV1 --post bronchodilation 2.02 on 2026-03-23; FEV1 measured/predicted 74 on 2026-03-23; Forced vital capacity [Volume] Respiratory system --post bronchodilation 2.93 on 2026-03-23; FEV1/FVC --post bronchodilation 0.69 on 2026-03-23; IgG [Mass/volume] in Serum or Plasma 1180 on 2026-03-23; IgA [Mass/volume] in Serum or Plasma 236 on 2026-03-23; IgM [Mass/volume] in Serum or Plasma 142 on 2026-03-23; IgE [Units/volume] in Serum or Plasma 38 on 2026-03-23; Aspergillus fumigatus IgE Ab [Units/volume] in Serum 0.08 on 2026-03-23; DXA Lumbar spine [Z-score] Bone density -1.4 on 2026-04-20; DXA Femur [Z-score] Bone density -1.1 on 2026-04-20; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-07-13; Total score [AUDIT-C] 0 on 2026-07-13 [S]
Strengths and supports: Supports: her writing, her correspondents, her sisters' company, and a strong sense of humour; financially independent through a legacy [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic cough with daily yellow sputum, occasional streaks of blood, and breathlessness on stairs, worse in winter, for several years after an illness with blood in the sputum about eight years ago; tuberculosis, nontuberculous mycobacteria and bronchiectasis to be distinguished | resolved | confirmed | R05.3 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis at the consultation; it echoes her documented chest illness (D). |
| Non-cystic fibrosis bronchiectasis of the left lower lobe and lingula with chronic Haemophilus influenzae infection and mild airflow obstruction (Bronchiectasis Severity Index 3, mild); tuberculosis and nontuberculous mycobacterial disease excluded; synthetic modern diagnosis chosen for a historical chest illness whose cause is disputed | active | confirmed | J47.9 | S — Synthetic modern diagnosis; the nature of her historical chest illness remains undetermined (R, disputed). |
| Long-term prescribed opioid therapy (oral morphine 20 mg a day for many years, for cough, sleeplessness and palpitations), with expected physiological dependence; no opioid use disorder on DSM-5-TR assessment | active | confirmed | Z79.891 | S — Synthetic modern problem anchored to her documented prescribed opium (D); tolerance and withdrawal on prescribed opioids do not count toward opioid use disorder. |
| Prolonged grief disorder after the drowning of her closest brother five years ago, with yearning, self-blame, avoidance of reminders of the sea, and depressive symptoms (PHQ-9 12); no suicidal ideation | active | confirmed | F43.81 | S — Synthetic modern diagnosis anchored to her documented bereavement (D); not a claim about her real mental health. |
| Vitamin D deficiency (25-hydroxyvitamin D 15 ng/mL) in a woman who rarely goes outdoors | resolved | confirmed | E55.9 | S — Synthetic finding at intake; repleted by twelve weeks. |
| Underweight (BMI 16.8) with a small appetite | active | confirmed | R63.6 | S — Synthetic finding at intake. |
| Exacerbation of bronchiectasis (more sputum, purulent sputum, more cough and breathlessness for three days, with low-grade fever), treated with amoxicillin for 14 days and more frequent airway clearance; resolved | resolved | confirmed | J47.1 | S — Synthetic intercurrent exacerbation; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-16 | Hemoglobin [Mass/volume] in Blood | 12.3 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-03-16 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 88 | fL | 80-100 fL | Normal | S |
| 2026-03-16 | Leukocytes [#/volume] in Blood by Automated count | 8.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-16 | Eosinophils [#/volume] in Blood | 0.21 | 10*3/uL | 0-0.5 10*3/uL | Normal | S |
| 2026-03-16 | Platelets [#/volume] in Blood by Automated count | 352 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-16 | C reactive protein [Mass/volume] in Serum or Plasma | 8.4 | mg/L | <=5 mg/L | High | S |
| 2026-03-16 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-16 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.66 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-03-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 114 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-16 | Glucose [Mass/volume] in Serum or Plasma | 84 | mg/dL | 70-139 mg/dL | Normal | S |
| 2026-03-16 | Calcium [Mass/volume] in Serum or Plasma | 9.2 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-16 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 15 | ng/mL | 30 to 100 ng/mL sufficient; below 20 ng/mL deficient | Low | S |
| 2026-03-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 12 | {score} | S | ||
| 2026-03-16 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 2026-03-23 | FEV1 --post bronchodilation | 2.02 | L | Lower limit of normal for her age, sex and height | Low | S |
| 2026-03-23 | FEV1 measured/predicted | 74 | % | >=80% | Low | S |
| 2026-03-23 | Forced vital capacity [Volume] Respiratory system --post bronchodilation | 2.93 | L | Lower limit of normal for her age, sex and height | Normal | S |
| 2026-03-23 | FEV1/FVC --post bronchodilation | 0.69 | {ratio} | Lower limit of normal for her age about 0.72 | Low | S |
| 2026-03-23 | IgG [Mass/volume] in Serum or Plasma | 1180 | mg/dL | 700-1600 mg/dL | Normal | S |
| 2026-03-23 | IgA [Mass/volume] in Serum or Plasma | 236 | mg/dL | 70-400 mg/dL | Normal | S |
| 2026-03-23 | IgM [Mass/volume] in Serum or Plasma | 142 | mg/dL | 40-230 mg/dL | Normal | S |
| 2026-03-23 | IgE [Units/volume] in Serum or Plasma | 38 | [IU]/mL | <=100 [IU]/mL | Normal | S |
| 2026-03-23 | Aspergillus fumigatus IgE Ab [Units/volume] in Serum | 0.08 | k[IU]/L | Below 0.35 kU/L: negative | Normal | S |
| 2026-04-20 | DXA Lumbar spine [Z-score] Bone density | -1.4 | {Z-score} | Above -2.0 is within the expected range for age | Normal | S |
| 2026-04-20 | DXA Femur [Z-score] Bone density | -1.1 | {Z-score} | Above -2.0 is within the expected range for age | Normal | S |
| 2026-04-20 | C reactive protein [Mass/volume] in Serum or Plasma | 4.1 | mg/L | <=5 mg/L | Normal | S |
| 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 10 | {score} | S | ||
| 2026-06-15 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30 to 100 ng/mL sufficient; below 20 ng/mL deficient | Normal | S |
| 2026-06-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-06-15 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S | ||
| 2026-10-19 | C reactive protein [Mass/volume] in Serum or Plasma | 3.2 | mg/L | <=5 mg/L | Normal | S |
| 2026-10-19 | Leukocytes [#/volume] in Blood by Automated count | 7.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-08-10 | C reactive protein [Mass/volume] in Serum or Plasma | 38 | mg/L | <=5 mg/L | High | S |
| 2026-08-10 | Leukocytes [#/volume] in Blood by Automated count | 11.8 | 10*3/uL | 4-11 10*3/uL | High | S |
| 2026-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-07-13 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-16 | Body height | 157 | cm | S |
| 2026-03-16 | Body weight | 41.5 | kg | S |
| 2026-03-16 | Body mass index (BMI) [Ratio] | 16.8 | kg/m2 | S |
| 2026-03-16 | Systolic blood pressure | 102 | mm[Hg] | S |
| 2026-03-16 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-03-16 | Heart rate | 96 | /min | S |
| 2026-03-16 | Respiratory rate | 18 | /min | S |
| 2026-03-16 | Body temperature | 36.9 | Cel | S |
| 2026-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 2026-03-23 | Body height | 157 | cm | S |
| 2026-03-23 | Body weight | 41.6 | kg | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 16.9 | kg/m2 | S |
| 2026-03-23 | Systolic blood pressure | 100 | mm[Hg] | S |
| 2026-03-23 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-03-23 | Heart rate | 92 | /min | S |
| 2026-03-23 | Respiratory rate | 18 | /min | S |
| 2026-03-23 | Body temperature | 36.8 | Cel | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 2026-04-20 | Body height | 157 | cm | S |
| 2026-04-20 | Body weight | 42.4 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 17.2 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 88 | /min | S |
| 2026-04-20 | Respiratory rate | 16 | /min | S |
| 2026-04-20 | Body temperature | 36.7 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-06-15 | Body height | 157 | cm | S |
| 2026-06-15 | Body weight | 43.3 | kg | S |
| 2026-06-15 | Body mass index (BMI) [Ratio] | 17.6 | kg/m2 | S |
| 2026-06-15 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-06-15 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-06-15 | Heart rate | 84 | /min | S |
| 2026-06-15 | Respiratory rate | 16 | /min | S |
| 2026-06-15 | Body temperature | 36.7 | Cel | S |
| 2026-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-10-19 | Body height | 157 | cm | S |
| 2026-10-19 | Body weight | 44.2 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 17.9 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 82 | /min | S |
| 2026-10-19 | Respiratory rate | 16 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-08-10 | Body height | 157 | cm | S |
| 2026-08-10 | Body weight | 43.4 | kg | S |
| 2026-08-10 | Body mass index (BMI) [Ratio] | 17.6 | kg/m2 | S |
| 2026-08-10 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-08-10 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-08-10 | Heart rate | 102 | /min | S |
| 2026-08-10 | Respiratory rate | 20 | /min | S |
| 2026-08-10 | Body temperature | 37.9 | Cel | S |
| 2026-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 2026-07-13 | Body height | 157 | cm | S |
| 2026-07-13 | Body weight | 43.8 | kg | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 17.8 | kg/m2 | S |
| 2026-07-13 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-07-13 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-07-13 | Heart rate | 82 | /min | S |
| 2026-07-13 | Respiratory rate | 16 | /min | S |
| 2026-07-13 | Body temperature | 36.7 | Cel | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-16 | New patient visit for chronic cough with blood-streaked sputum, a long-term opioid prescription, and grief, with tuberculosis testing and urgent pulmonology referral | finished | S |
| 2026-03-23 | Pulmonology consultation with CT of the chest and spirometry, diagnosis of bronchiectasis, and the start of airway clearance | finished | S |
| 2026-04-20 | Four-week review: mycobacterial cultures, airway clearance, bone density, grief therapy, and her choice about the opioid dose | finished | S |
| 2026-06-15 | Three-month review: final mycobacterial cultures, vitamin D, mood, safety, and the opioid dose | finished | S |
| 2026-10-19 | Seven-month review after an exacerbation: lungs, opioid therapy, mood, safety, weight, and vaccines | finished | S |
| 2026-08-10 | Same-day sick visit for an exacerbation of bronchiectasis | finished | S |
| 2026-07-13 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Evaluation of chronic cough with blood-streaked sputum: three sputum samples at least eight hours apart, one early morning, for acid-fast smear, nucleic acid amplification and mycobacterial culture (including nontuberculous mycobacteria) and routine bacterial culture; interferon-gamma release assay and HIV test; blood count, CRP and metabolic panel; CT of the chest within a week; a mask in shared spaces until the smears are negative; call 911 or go to the emergency department for more than a few teaspoons of blood, blood with breathlessness, or chest pain | completed | GL-ATS-TB-2017, GL-NTM-2020, GL-BTS-BE-2019 | S |
| Urgent pulmonology consultation within one week for chronic productive cough with blood-streaked sputum: exclude tuberculosis, confirm or exclude bronchiectasis and plan its care, and advise on opioids and the lungs | completed | GL-BTS-BE-2019, GL-ATS-TB-2017 | S |
| Long-term opioid therapy review: prescription monitoring program checked (one prescriber, one pharmacy), urine drug test consistent with morphine only, naloxone prescribed and taught, no benzodiazepines or other sedatives, DSM-5-TR assessment (no opioid use disorder), dose continued unchanged with no forced taper, benefits and harms reviewed at every visit and at least every three months, the monitoring program checked with every prescription, and buprenorphine offered if opioid use disorder ever develops | completed | GL-CDC-OPIOID-2022, GL-DSM5TR-2022 | S |
| Prolonged grief disorder therapy with the clinic psychologist, weekly for sixteen sessions, by video at first so she need not travel; PHQ-9 at every visit | completed | GL-PGD-2016, GL-DSM5TR-2022, GL-CMID-2026 | S |
| Collaborative safety plan with warning signs, coping steps, people to contact, the clinic number and the 988 Suicide & Crisis Lifeline; morphine kept in a locked box with only the current bottle out; safety reviewed at every visit | completed | GL-SUICIDE-2024, GL-CDC-OPIOID-2022 | S |
| Bone and nutrition: vitamin D3 2000 units daily with a recheck at twelve weeks; DXA for low weight, vitamin D deficiency, limited weight-bearing and long-term opioid therapy; calcium-rich foods, small frequent meals and an oral supplement drink with the clinic dietitian; weight at every visit | completed | GL-CMID-2026 | S |
| Bronchiectasis care: active cycle of breathing with an oscillating positive expiratory pressure device twice daily, taught by the respiratory physiotherapist; a home exercise program; influenza, pneumococcal and COVID-19 vaccines; a written exacerbation plan with a sputum sample and amoxicillin 500 mg three times daily for 14 days; sputum culture at each review and spirometry, Bronchiectasis Severity Index and mycobacterial culture yearly; no long-term macrolide while exacerbations are fewer than three a year | completed | GL-BTS-BE-2019, GL-ERS-BE-2017 | S |
| Opioid dose reduction at her request: morphine lowered by about 10 percent at a time (to 18 mg a day now), with each step held at least four weeks, paused at any time she wishes, and never forced; withdrawal symptoms and sleep reviewed at each visit | completed | GL-CDC-OPIOID-2022 | S |
| Exacerbation of bronchiectasis: sputum culture before the first dose; amoxicillin 500 mg three times daily for 14 days; airway clearance three to four times a day; fluids; the morphine dose unchanged and no added cough suppressant; nurse phone check in two days; call 911 for more than a few teaspoons of blood, worsening breathlessness or confusion | completed | GL-BTS-BE-2019, GL-CDC-OPIOID-2022 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Tuberculosis excluded and a diagnosis for the cough within two weeks | 2026-03-23 | completed | Smears, NAAT and IGRA negative within a week; bronchiectasis diagnosed by CT at one week | S |
| Airway clearance twice daily, with less sputum and no blood in it, by three months | 2026-06-15 | completed | Airway clearance twice daily; sputum down from about four to one tablespoon a day; no blood since the first month | S |
| Safe opioid therapy: naloxone at home, no overdose or sedation, and any dose change only by her choice | 2026-10-19 | completed | Naloxone at home; no sedation; she chose to reduce from 20 to 14 mg a day over seven months without troublesome withdrawal | S |
| Response of grief and depressive symptoms (PHQ-9 down by at least half) by six months | 2026-10-19 | completed | PHQ-9 5 from 12 after sixteen sessions of grief therapy; she can speak of her brother | S |
| Weight up toward a BMI of 18.5 (45.6 kg) by seven months | 2026-10-19 | active | 44.2 kg from 41.5 kg (BMI 17.9); still gaining | S |
| Vitamin D above 30 ng/mL by twelve weeks | 2026-06-15 | completed | 34 ng/mL | S |
Structured synthetic safety assessment on 2026-03-16: current ideation absent, intent absent, plan absent. Outpatient care with a collaborative safety plan, the 988 Suicide & Crisis Lifeline, her morphine kept in a locked box with only the current bottle out, naloxone at home, and review at every visit [S]